more

Novartis (NVS)

(Delayed Data from NYSE)

$102.10 USD

+1.89 (1.89%)

Updated May 10, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

Bottom 39% (154 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for NVS

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Established Brands: Afi...	--	512	417	417	1,083	1,539
Revenues: Hematology: Promacta/Re...		2,269	2,088	2,016	1,738	1,416
Revenues: Other Promoted Brands: ...	--	--	479	584	623	630
Revenues: Established Brands: Gal...		692	859	1,092	1,199	1,297
Revenues: Established Brands: Exf...		713	743	901	980	1,025
Revenues: Hematology: Kymriah - T...		508	536	587	474	278
Revenues: Hematology: Tasigna - T...		1,848	1,923	2,060	1,958	1,880
Revenues: Other Promoted Brands: ...		1,475	1,874	2,160	1,933	2,086
Revenues: Established Brands: Gle...	--	561	745	1,024	1,188	1,263
Revenues: Established Brands: San...		1,314	1,238	1,413	1,439	1,585
Revenues: Hematology: Jakavi - To...		1,720	1,561	1,595	1,339	1,114
Revenues: Established Brands: Dio...		613	652	773	1,003	1,064
Total Neuroscience [$M]		4,043	3,038	5,007	--	--
Neuroscience: Mayzent [$M]	--	392	357	281	--	--
Solid Tumors: Lutathera [$M]		605	471	475	--	--
Solid Tumors: Piqray [$M]		505	373	329	--	--
Solid Tumors: Pluvicto [$M]		980	271	--	--	--
Solid Tumors: Tabrecta [$M]	--	154	133	90	--	--
Other Promoted Brands: Beovu [$M]	--	--	203	186	--	--
Neuroscience: Zolgensma [$M]		1,214	1,370	1,351	--	--
Hematology: Adakveo [$M]	--	195	194	164	--	--
Hematology: Scemblix [$M]		413	149	7	--	--
Neuroscience: Aimovig [$M]		266	218	215	--	--
Cardiovascular: Leqvio [$M]		355	112	12	--	--
Total Immunology [$M]		7,798	7,287	7,205	--	--
Total Cardiovascular [$M]		6,391	4,756	3,560	--	--
Other Promoted Brands: Other resp...	--	--	84	53	--	--
Total Promoted Brands [$M]		31,822	26,257	29,754	--	--
Established Brands: Contract manu...		1,490	1,200	108	--	--
Established Brands: Other [$M]		5,427	6,113	4,257	--	--
Total Established Brand [$M]		13,618	15,949	12,241	--	--
Neuroscience: Kesimpta [$M]		2,171	1,092	372	--	--
Revenues: Net sales to third part...		45,440	42,206	51,626	48,659	47,445
Revenues: Other revenues [$M]		1,220	1,255	1,251	1,239	1,179
Revenues: Cardiovascular: Entrest...		6,035	4,644	1,836	2,497	1,726
Revenues: Immunology:Cosentyx - T...		4,980	4,788	3,548	3,995	3,551
Revenues: Immunology: Xolair - To...		1,463	1,365	1,428	1,251	1,173
Revenues: Immunology: Ilaris - To...		1,355	1,133	1,059	873	671
Revenues: Neuroscience: Gilenya -...		925	2,013	2,787	3,003	3,223
Revenues: Solid Tumors: Tafinlar ...		1,922	1,770	1,693	1,542	1,338
Revenues: Solid Tumors: Kisqali -...		2,080	1,231	937	687	480
Revenues: Solid Tumors: Votrient ...	--	390	474	577	635	755
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Revenues: Hematology: Promacta/Re...		1,205	1,083	947	833	691
Revenues: Immunology: Cosentyx - ...		2,636	2,770	2,883	2,516	2,220
Revenues: Immunology: Cosentyx - ...		2,344	2,018	4,718	1,479	1,331
Revenues: Established Brands: Exf...		700	729	887	964	1,012
Revenues: Established Brands: Gle...	--	150	205	263	315	334
Revenues: Established Brands: Gle...	--	411	540	761	873	929
Revenues: Established Brands: San...		829	800	843	837	881
Revenues: Established Brands: San...		485	438	570	602	704
Revenues: Immunology: Ilaris - US...		686	570	501	400	304
Revenues: Immunology: Ilaris - Re...		669	563	558	473	367
Revenues: Established Brands: Dio...		52	55	51	124	86
Revenues: Established Brands: Dio...		561	597	722	879	978
Revenues: Solid Tumors: Kisqali -...		1,032	472	339	318	250
Revenues: Solid Tumors: Kisqali -...		1,048	759	598	369	230
Neuroscience: Zolgensma - US [$M]		372	434	469	--	--
Neuroscience: Zolgensma - ROW [$M...		842	936	882	--	--
Revenues: Cardiovascular: Entrest...		3,067	2,354	1,712	1,277	925
Revenues: Cardiovascular: Entrest...		2,968	2,290	1,836	1,220	801
Revenues: Neuroscience: Gilenya -...		359	1,153	1,427	1,562	1,736
Revenues: Neuroscience: Gilenya -...		566	860	1,360	1,441	1,487
Revenues: Hematology: Tasigna - U...		884	877	882	859	804
Revenues: Hematology: Tasigna - R...		964	1,046	1,178	1,099	1,076
Revenues: Solid Tumors: Tafinlar ...		791	678	606	569	481
Revenues: Solid Tumors: Tafinlar ...		1,131	1,092	1,087	973	857
Revenues: Established Brands: Exf...		13	14	14	16	13
Revenues: Hematology: Promacta/Re...		1,064	1,005	1,069	905	725

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Revenues: Established Brands: Afi...	--	--	97	85	116	110
Revenues: Hematology: Promacta/Re...		520	563	576	583	547
Revenues: Other Promoted Brands: ...	--	--	--	104	114	114
Revenues: Established Brands: Gal...		149	153	181	175	183
Revenues: Established Brands: Exf...		192	156	187	184	186
Revenues: Hematology: Kymriah - T...		120	120	124	129	135
Revenues: Hematology: Tasigna - T...		395	446	464	476	462
Revenues: Other Promoted Brands: ...		314	301	363	395	416
Revenues: Established Brands: Gle...	--	--	128	144	142	147
Revenues: Established Brands: San...		355	316	338	331	329
Revenues: Hematology: Jakavi - To...		478	444	427	435	414
Revenues: Established Brands: Dio...		140	147	153	155	158
Total Neuroscience [$M]		1,009	1,102	1,137	961	754
Neuroscience: Mayzent [$M]	--	--	106	103	94	89
Solid Tumors: Lutathera [$M]		169	147	159	150	149
Solid Tumors: Piqray [$M]		109	131	128	130	116
Solid Tumors: Pluvicto [$M]		310	273	256	240	211
Solid Tumors: Tabrecta [$M]	--	--	41	36	41	36
Other Promoted Brands: Beovu [$M]	--	--	--	47	53	51
Neuroscience: Zolgensma [$M]		295	286	308	311	309
Hematology: Adakveo [$M]	--	--	45	45	53	52
Hematology: Scemblix [$M]		136	125	106	106	76
Neuroscience: Aimovig [$M]		76	69	69	67	61
Cardiovascular: Leqvio [$M]		151	123	90	78	64
Total Immunology [$M]		2,081	2,057	2,033	1,950	1,758
Total Cardiovascular [$M]		2,030	1,759	1,575	1,594	1,463
Other Promoted Brands: Other resp...	--	--	--	21	23	25
Total Promoted Brands [$M]		8,464	8,426	8,448	8,229	6,959
Established Brands: Contract manu...		279	302	471	132	375
Established Brands: Other [$M]		1,761	1,243	1,142	1,115	1,960
Total Established Brand [$M]		3,365	2,997	3,334	3,014	3,839
Neuroscience: Kesimpta [$M]		637	641	657	489	384
Revenues: Net sales to third part...		11,829	9,238	11,782	13,622	10,798
Revenues: Other revenues [$M]		291	347	310	314	249
Revenues: Cardiovascular: Entrest...		1,879	1,635	1,485	1,516	1,399
Revenues: Immunology:Cosentyx - T...		1,326	1,303	1,329	1,272	1,076
Revenues: Immunology: Xolair - To...		399	378	369	362	354
Revenues: Immunology: Ilaris - To...		356	376	335	316	328
Revenues: Neuroscience: Gilenya -...		175	154	270	269	232
Revenues: Solid Tumors: Tafinlar ...		474	486	482	496	458
Revenues: Solid Tumors: Kisqali -...		627	610	562	493	415
Revenues: Solid Tumors: Votrient ...	--	--	77	102	106	105
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Revenues: Hematology: Promacta/Re...		266	301	314	313	277
Revenues: Immunology: Cosentyx - ...		661	741	717	650	528
Revenues: Immunology: Cosentyx - ...		665	562	612	622	548
Revenues: Established Brands: Exf...		188	154	184	180	--
Revenues: Established Brands: Gle...	--	--	32	41	39	38
Revenues: Established Brands: Gle...	--	--	96	103	103	109
Revenues: Established Brands: San...		239	199	218	203	209
Revenues: Established Brands: San...		116	117	120	128	120
Revenues: Immunology: Ilaris - US...		166	200	182	163	141
Revenues: Immunology: Ilaris - Re...		190	176	153	153	187
Revenues: Established Brands: Dio...		9	14	11	12	15
Revenues: Established Brands: Dio...		131	133	142	143	143
Revenues: Solid Tumors: Kisqali -...		313	332	294	224	182
Revenues: Solid Tumors: Kisqali -...		314	278	268	269	233
Neuroscience: Zolgensma - US [$M]		104	90	89	84	109
Neuroscience: Zolgensma - ROW [$M...		191	196	219	227	200
Revenues: Cardiovascular: Entrest...		948	880	728	755	704
Revenues: Cardiovascular: Entrest...		931	755	757	761	695
Revenues: Neuroscience: Gilenya -...		52	55	120	104	80
Revenues: Neuroscience: Gilenya -...		123	99	150	165	152
Revenues: Hematology: Tasigna - U...		174	220	221	232	211
Revenues: Hematology: Tasigna - R...		221	226	243	244	251
Revenues: Solid Tumors: Tafinlar ...		184	200	201	196	194
Revenues: Solid Tumors: Tafinlar ...		290	286	281	300	264
Revenues: Established Brands: Exf...		4	2	3	4	4
Revenues: Hematology: Promacta/Re...		254	262	262	270	270

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators